High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients

被引：22

作者：

Egawa, C ^{[1
]}

Miyoshi, Y ^{[1
]}

Taguchi, T ^{[1
]}

Tamaki, Y ^{[1
]}

Noguchi, S ^{[1
]}

机构：

[1] Osaka Univ, Sch Med, Dept Surg Oncol, Suita, Osaka 5650871, Japan

来源：

INTERNATIONAL JOURNAL OF CANCER | 2002年 / 98卷 / 06期

关键词：

breast cancer; BRCA2; prognosis; ER; histologic grade;

D O I：

10.1002/ijc.10231

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognostic significance of BRCA2 mRNA levels in tumor tissues was studied in sporadic breast cancer patients. BRCA2 mRNA levels were determined by real-time PCR. Histologic grade III tumors showed significantly (p = 0.001) higher BRCA2 mRNA levels (0.828 +/- 0.102 BRCA2/beta-glucuronidase mRNA ratio, mean +/- SE) than histologic grade I and II tumors (0.438 +/- 0.055) and estrogen receptor (ER)-negative tumors (0.773 +/- 0.102) showed a nonsignificant (p = 0.072) trend toward an increase in BRCA2 mRNA levels compared to ER-positive tumors (0.541 +/- 0.079). Other clinicopathologic parameters, such as menopausal status, lymph node status and tumor size, were not significantly associated with BRCA2 mRNA levels. Patients with high BRCA2 mRNA levels showed a significantly (p = 0.006) lower 5-year disease free survival rate (63%) than those with low levels (94%). Lymph node metastases, ER negativity and high histologic grade were also significantly (p < 0.05) associated with poor prognosis. Multivariate analysis revealed that BRCA2 mRNA levels were a significant prognostic factor, being independent of the other conventional prognostic factors. Our results suggest that BRCA2 mRNA levels might serve as a clinically useful prognostic factor in breast cancer patients. (C) 2002 Wiley-Liss, Inc.

引用

页码：879 / 882

页数：4

共 35 条

[1] Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer [J].

Beckmann, MW ;

Picard, F ;

An, HX ;

vanRoeyen, CRC ;

Dominik, SI ;

Mosny, DS ;

Schnurch, HG ;

Bender, HG ;

Niederacher, D .

BRITISH JOURNAL OF CANCER, 1996, 73 (10) :1220-1226

[2]

Bernard-Gallon D, 2000, INT J CANCER, V86, P453, DOI 10.1002/(SICI)1097-0215(20000515)86:4<453::AID-IJC1>3.0.CO

[3]

2-F

[4] Overexpression of BRCA2 gene in sporadic breast tumours [J].

Bièche, I ;

Noguès, C ;

Lidereau, R .

ONCOGENE, 1999, 18 (37) :5232-5238

[5]

Chassevent A, 2001, CLIN CANCER RES, V7, P909

[6] Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers [J].

Collins, N ;

Wooster, R ;

Stratton, MR .

BRITISH JOURNAL OF CANCER, 1997, 76 (09) :1150-1156

[7] Quantitative analysis of BRCA1 and BRCA2 mRNA expression in sporadic breast carcinomas and its relationship with clinicopathological characteristics [J].

Egawa, C ;

Miyoshi, Y ;

Taguchi, T ;

Tamaki, Y ;

Noguchi, S .

JAPANESE JOURNAL OF CANCER RESEARCH, 2001, 92 (06) :624-630

[8]

Egawa C, 2001, INT J CANCER, V95, P255, DOI 10.1002/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO

[9]

2-O

[10]

ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300

← 1 2 3 4 →